Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.88 |
| ▸ | EGFR | P00533 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299050 | 0.86 | ENPP1 (0.86) | ENPP1EGFRKDRFLT1FGFR1 | |
| SCHEMBL8649615 | 0.86 | ENPP1 (0.86) | ENPP1EGFRKDRFLT1FGFR1 | |
| SCHEMBL1013257 | 0.86 | ENPP1 (0.88) | ENPP1EGFRALDH1A1FBP1 | |
| SCHEMBL163465 | 0.85 | ENPP1 (0.71) | ENPP1EGFRKDRFLT1GAK | |
| SCHEMBL29478510 | 0.85 | ENPP1 (0.71) | ENPP1EGFRKDRFLT1GAK | |
| SCHEMBL1507564 | 0.85 | ENPP1 (0.66) | ENPP1EGFRALDH1A1FBP1KDR | |
| Hydrochloric Acid SCHEMBL8307436 | 0.84 | ENPP1 (0.69) | ENPP1EGFRKDRFLT1GAK | |
| SCHEMBL1013021 | 0.81 | ENPP1 (0.79) | ENPP1EGFRALDH1A1KDRFLT1 | |
| SCHEMBL1013051 | 0.81 | ENPP1 (0.79) | ENPP1EGFRKDRFLT1FGFR1 | |
| SCHEMBL1015576 | 0.81 | ENPP1 (0.79) | ENPP1EGFRKDRFLT1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101878203-A | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents | NATCO PHARMA LTD | 2010-11-03 | — | — | CN | claimed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | claimed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | ENPP1 2315/4885EGFR 1213/4885ALDH1A1 856/4885 |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | ENPP1 2397/4885EGFR 1110/4885ALDH1A1 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.